Related references
Note: Only part of the references are listed.Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure
Xuefang Bai et al.
BIOCHEMISTRY (2008)
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study
Antonio M. T. Martins Do Canto et al.
JOURNAL OF PEPTIDE SCIENCE (2008)
Selection of T1249-resistant human immunodeficiency virus type 1 variants
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2008)
Viral membrane fusion
Stephen C. Harrison
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm
Gregory B. Melikyan
RETROVIROLOGY (2008)
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine development
Amy Jacobs et al.
VACCINE (2008)
HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets
Sjoerd J. De Vries et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2007)
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249
T. Melby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors
M. Porotto et al.
JOURNAL OF VIROLOGY (2007)
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
John J. Dwyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue
Raghavan Chinnadurai et al.
JOURNAL OF VIROLOGY (2007)
HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides
Shuwen Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
Stefano Aquaro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Kinetic dependence to HIV-1 entry inhibition
H. Kirby Steger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2
T. Melby et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
Virus membrane-fusion proteins: more than one way to make a hairpin
M Kielian et al.
NATURE REVIEWS MICROBIOLOGY (2006)
Design and characterization of viral polypeptide inhibitors targeting newcastle disease virus fusion
JQ Zhu et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro
M Mink et al.
JOURNAL OF VIROLOGY (2005)
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors
R Chinnadurai et al.
AIDS (2005)
Inhibition of murine leukemia virus envelope protein (Env) processing by intracellular expression of the Env N-terminal heptad repeat region
W Ou et al.
JOURNAL OF VIROLOGY (2005)
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen
JP Lalezari et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
JJ Eron et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Identification of protein-protein interaction sites from docking energy landscapes
J Fernández-Recio et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates
PR Sista et al.
AIDS (2004)
Resistance to enfuvirtide, the first HIV fusion inhibitor
ML Greenberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure
RW Sanders et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2004)
Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides
BJ Bosch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
CE Baldwin et al.
JOURNAL OF VIROLOGY (2004)
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase
K Diallo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20
VD Trivedi et al.
PROTEIN ENGINEERING (2003)
Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion
EX Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
HADDOCK: A protein-protein docking approach based on biochemical or biophysical information
C Dominguez et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
RW Sanders et al.
JOURNAL OF VIROLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis
M Lu et al.
JOURNAL OF VIROLOGY (2001)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G
RE Jeeninga et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
